Vancouver, Canada (Newsfile Corp. - February 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative
Completed NVG-291 dosing of subjects in Phase 1 clinical trialPhase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023NVG-291 has been demonstrated in preclinical
Vancouver, British Columbia (Newsfile Corp. - November 15, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing
NervGen Pharma Grants Stock Options streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AMERICAN NEUROLOGICAL ASSOCIATION ANNUAL MEETINGEUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS Vancouver, British Columbia (Newsfile Corp. - October 20, 2022) - NervGen Pharma Corp.